Men with terminal prostate cancer may benefit from new drugs.
Lutetium, which he extended the survival of patients with widespread disease by four months, is safe and effective to use.
Approved by The Medicines and Healthcare Regulatory Agency. The
drug oversight agency will decide in the fall whether to recommend deploying the NHS .
More than 52,000 men are diagnosed with prostate cancer annually, and 12,000 die.
About 3,500 people develop progressive disease that does not respond to usual treatment.
Intravenously administered lutetium binds tocancer cells and delivers a tumor-destroying radioactive payload.
"This is a major clinical advance," said Professor Johan de Bono of the Royal Marsden Hospital in West London.
